These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 3529880)

  • 1. Data quality in post-marketing surveillance.
    Girard M
    Adverse Drug React Acute Poisoning Rev; 1986; 5(2):87-95. PubMed ID: 3529880
    [No Abstract]   [Full Text] [Related]  

  • 2. Concerns with postmarketing surveillance.
    Norvell MJ; Anderson RJ
    Am J Hosp Pharm; 1984 Jan; 41(1):54, 56. PubMed ID: 6695933
    [No Abstract]   [Full Text] [Related]  

  • 3. Manufacturer-hospital collaboration to improve patient care quality.
    DeGasparis P; Magill KA; Milone T
    Hosp Top; 1983; 61(4):15-6. PubMed ID: 10260122
    [No Abstract]   [Full Text] [Related]  

  • 4. Policy issues concerning antimicrobials: problems with the regulatory process governing their introduction.
    Simon HJ
    Hosp Formul; 1985 May; 20(5):629-31, 634. PubMed ID: 10271104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidelines on postmarketing surveillance. Joint committee of ABPI, BMA, CSM, and RCGP.
    Joint committee of ABPI, BMA, CSM, and RCGP
    Br Med J (Clin Res Ed); 1988 Feb; 296(6619):399-400. PubMed ID: 3125920
    [No Abstract]   [Full Text] [Related]  

  • 6. [Quality control: observation record on the use of pliable bags].
    Avenard G; Cavalier J; Couquelet M
    Rev Fr Transfus Immunohematol; 1985 Feb; 28(1):45-9. PubMed ID: 3992127
    [No Abstract]   [Full Text] [Related]  

  • 7. Record linkage studies for postmarketing drug surveillance: data quality and validity considerations.
    Stergachis AS
    Drug Intell Clin Pharm; 1988 Feb; 22(2):157-61. PubMed ID: 3349931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The observational post-marketing study--an observation of use].
    Meister W
    Dtsch Med Wochenschr; 2003 Apr; 128(16):859-62. PubMed ID: 12701030
    [No Abstract]   [Full Text] [Related]  

  • 9. [Planning, realization and evaluation of post-marketing surveillance studies. Recommendations of the Society for Phytotherapy].
    Kraft K; Loew D; Schneider B; Kemper FH
    Arzneimittelforschung; 1997 Aug; 47(8):990-4. PubMed ID: 9341095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The need for human data: the role of clinical trials and postmarketing surveillance in the safety assessment of macronutrient substitutes.
    Forbes AL
    Regul Toxicol Pharmacol; 1996 Feb; 23(1 Pt 2):S20-1; discussion S31-7. PubMed ID: 8801611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Post-marketing surveillance of a drug with anti-sclerotic activity. Preliminary results].
    Donati C; Barbi G; Riva M
    Recenti Prog Med; 1986; 77(7-8):362-8. PubMed ID: 3786937
    [No Abstract]   [Full Text] [Related]  

  • 12. [Drug surveillance. Monitoring the side-effects of drugs in the post-marketing phase: cimetidine. II].
    Mariani L; Minora T
    Clin Ter; 1984 Apr; 109(2):109-25. PubMed ID: 6234121
    [No Abstract]   [Full Text] [Related]  

  • 13. Round table: Post-marketing evaluation of fertility-regulating drugs as viewed by the pharmaceutical industry.
    Hum Reprod; 1987 Apr; 2(3):241-63. PubMed ID: 3597744
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of the assessment of the severity on the frequency of adverse drug reactions (ADRs).
    Zilleruelo I; Espinoza E; Ruiz I
    Int J Clin Pharmacol Ther Toxicol; 1987 Jun; 25(6):328-33. PubMed ID: 3623738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-marketing surveillance of licensed medicinal and other products.
    Griffin JP
    Health Trends; 1981 Aug; 13(3):85-8. PubMed ID: 10258571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postmarketing surveillance study of a non-chlorofluorocarbon inhaler Postmarketing surveillance studies remain unethical.
    Patterson C
    BMJ; 1999 Mar; 318(7186):810-11. PubMed ID: 10215393
    [No Abstract]   [Full Text] [Related]  

  • 17. Meeting US and European supplier control requirements.
    Donawa M
    Med Device Technol; 2009; 20(3):24-7. PubMed ID: 19626952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Not enough warning. GAO report finds FDA's medical device monitoring lacking.
    Hensley S
    Mod Healthc; 1997 Mar; 27(10):102, 104. PubMed ID: 10165267
    [No Abstract]   [Full Text] [Related]  

  • 19. Marketing medical devices in Japan.
    Ohashi J
    Med Device Technol; 1998; 9(1):32-3, 36-7. PubMed ID: 10176143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post marketing surveillance. Traps for the unwary.
    Marley J; Mant A
    Aust Fam Physician; 1993 Jun; 22(6):1009-11, 1013. PubMed ID: 8338446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.